Home » EMEA Outlines Pediatric Plans for Allergen Products
EMEA Outlines Pediatric Plans for Allergen Products
December 17, 2009
Drugmakers that have been selling allergen products in Germany under the “named-patient” basis must now get a German marketing authorization
by submitting applications that include dedicated pediatric clinical trials in Germany no later than Dec. 1, 2010. Includes the full text of EMEA Draft PIP for Allergen Products.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor